How does sapropterin change phenylalanine’s structure in the body?
Sapropterin (the active form of which is tetrahydrobiopterin, BH4) does not directly “transform” phenylalanine’s structure. Instead, it affects how the body handles phenylalanine by acting as a required cofactor for the enzyme phenylalanine hydroxylase (PAH). PAH uses BH4 to convert phenylalanine into another molecule, which effectively changes phenylalanine’s chemical form by redirecting it away from accumulation. [1]
What exact chemical change happens when BH4 is present?
With functional PAH and BH4 present, phenylalanine is hydroxylated (an -OH group is added) to form tyrosine. This removes phenylalanine from the pool of phenylalanine and increases tyrosine production. BH4 is essential for PAH’s catalytic cycle. [1]
What role does BH4 play if PAH is working properly?
Sapropterin works by restoring or supporting the BH4-dependent activity of PAH. When BH4 is available, PAH can carry out the hydroxylation step that turns phenylalanine into tyrosine. When BH4 is deficient or PAH lacks BH4 function, phenylalanine conversion drops, causing phenylalanine to build up. [1]
What happens if sapropterin is not used (or BH4/PAH function is impaired)?
If BH4 availability or PAH activity is insufficient, phenylalanine is not efficiently converted to tyrosine, so phenylalanine remains elevated rather than being chemically converted. That results in the biochemical hallmark of phenylketonuria (PKU). [1]
Clinical relevance: why this matters in PKU treatment
Because sapropterin supports BH4-dependent conversion of phenylalanine to tyrosine, it can lower blood phenylalanine levels in some people with certain forms of PKU, depending on how responsive their PAH system is to BH4. [1]
Sources:
[1] https://www.drugs.com/monograph/sapropterin.html